EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)

Navin Wewala, Yujin Kim, Katrina Sharples, Sarah Benge, Robert Cartwright, Alvin Tan, Louise Clement, Ying Huang, Sheridan Wilson, Marion Kuper-Hommel, Sarah Barton, Joanna Jones und 5 weitere

Supportive Care in Cancer · 2025

DOI: 10.1007/s00520-025-09528-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Navin Wewala und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Screening, Treatment and Support, Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral, Palmerston North Hospital, 50 Ruahine Street, Pal…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Nausea, Pantoprazole. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Delayed chemotherapy-induced nausea and vomiting (CINV) is a distressing effect of chemotherapy for early breast cancer (EBC), with rates exceeding 50%, despite multi-agent prophylaxis. We hypothesised that chemotherapy-induced alterations to the gastric environment may result in delayed CINV, and that pantoprazole, a proton pump inhibitor, may be effective prophylaxis by reducing stomach acid. METHODS: Using a randomised crossover design, we compared pantoprazole 40 mg once daily with placebo for 5 days at the start of each chemotherapy cycle, in addition to standard antiemetic prophylaxis in previously untreated patients undergoing chemotherapy for EBC. The primary endpoint was complete absence of nausea and vomiting during days 2-5. Secondary endpoints included nausea scores using the MASCC Antiemesis Tool (MAT), number of episodes of vomiting and participant preference over the same period. RESULTS: One hundred sixty participants were recruited from 10 New Zealand hospitals. There was a complete absence of delayed CINV in 51.4% of participants when taking pantoprazole versus 39.3% when taking placebo (OR = 2.2, 95% CI [1.18 to 4.12], P = 0.01). MAT scores for delayed nausea were significantly lower when participants were taking pantoprazole than when the same participants were taking placebo, P = 0.006. Pantoprazole was also preferred by 50.4% versus 25.2% preferring placebo, with no increase in adverse events. CONCLUSIONS: Pantoprazole is a cost-effective and safe agent, which reduces rates of delayed nausea and should be considered as prophylaxis in patients undergoing emetogenic chemotherapy. TRIAL REGISTRATION: The trial is registered in the US National Library of Medicine Clinical Trials Registry (Registration No. NCT03948477).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsNauseaPantoprazoleProton Pump InhibitorsVomitingAdultAgedFemaleHumansMiddle AgedChemotherapy, AdjuvantCross-Over StudiesDouble-Blind MethodNeoadjuvant TherapyNew Zealand

Stichwörter der Autor:innen

AntiemeticChemotherapy-induced dyspepsiaChemotherapy-induced nausea and vomitingDelayed nauseaPantoprazoleProton pump inhibitor

Substanzen

Antineoplastic AgentsPantoprazoleProton Pump Inhibitors

Autor:innen und Institutionen

  • Cancer Screening, Treatment and Support, Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral, Palmerston North Hospital, 50 Ruahine Street, Palmerston North, 4414, New Zealand. navin.wewala@midcentraldhb.govt.nz.
  • Cancer Trials New Zealand, Department of Oncology, University of Auckland, Auckland, New Zealand.
  • Department of Medicine, University of Otago, Dunedin, New Zealand.
  • Department of Oncology, Te Whatu Ora Waikato, Hamilton, New Zealand.
  • Auckland Regional Cancer and Blood Service, Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand.
  • Wellington Blood and Cancer Centre, Te Whatu Ora Capital, Coast, Hutt Valley and Wairarapa, Wellington, New Zealand.

Zitieren

APA

Wewala, N., Kim, Y., Sharples, K., Benge, S., Cartwright, R., Tan, A., Clement, L., Huang, Y., Wilson, S., Kuper-Hommel, M., Barton, S., Jones, J., Bremer, L., Hari Dass, P., Wrigley, A., Findlay, M., & Isaacs, R. (2025). Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN). Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09528-0

Vancouver

Wewala N, Kim Y, Sharples K, Benge S, Cartwright R, Tan A, et al. Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN). Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09528-0

BibTeX
@article{Wewala2025,
  author = {Wewala, Navin and Kim, Yujin and Sharples, Katrina and Benge, Sarah and Cartwright, Robert and Tan, Alvin and Clement, Louise and Huang, Ying and Wilson, Sheridan and Kuper-Hommel, Marion and Barton, Sarah and Jones, Joanna and Bremer, Louise and Hari Dass, Prashanth and Wrigley, Abbey and Findlay, Michael and Isaacs, Richard},
  title = {Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)},
  journal = {Supportive Care in Cancer},
  year = {2025},
  doi = {10.1007/s00520-025-09528-0}
}
Kostenlos starten →